Form 4: BridgeBio Pharma CEO Neil Kumar Reports Share Transfers

BridgeBio Pharma CEO Neil Kumar reported a transfer of shares, both directly and indirectly, on December 24, 2024.

Summary

• Neil Kumar, CEO of BridgeBio Pharma, reported a transaction involving the transfer of common stock on December 24, 2024.
• A total of 4,685,725 shares were transferred directly from Neil Kumar, and the same amount was transferred to a trust where he is a co-trustee.
• Following the transaction, Neil Kumar directly owns 211,718 shares and indirectly owns 5,698,447 shares through the Kumar Haldea Revocable Trust.
• He also indirectly owns 995,686 shares through the Kumar Haldea Family Irrevocable Trust.
• The transfer was a gift and did not involve any monetary transaction.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing and does not indicate any positive or negative sentiment.

Industry Context

This is a routine filing related to insider transactions and is common for executives of publicly traded companies.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, such as directors and officers, in accordance with SEC regulations.
• The reporting of share transfers as gifts is a common occurrence in these filings.
• The level of detail provided in this filing is consistent with what is expected for such transactions.

Stakeholder Impact

• The share transfer does not have a direct impact on stakeholders as it is a transfer of ownership and not a sale.

Key Dates

Keywords

BridgeBio Pharma, Neil Kumar, share transfer, common stock, beneficial ownership, SEC Form 4, insider trading